Shuttle Pharmaceuticals Holdings, Inc. ((SHPH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shuttle Pharmaceuticals Holdings, Inc. is conducting a Phase 2 study titled ‘Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter.’ The study aims to evaluate the safety and efficacy of ropidoxuridine, a radiation-sensitizing agent, in patients with this specific type of glioblastoma undergoing standard radiotherapy. This research is significant as it explores potential improvements in treatment outcomes for a challenging cancer type.
The intervention being tested is ropidoxuridine, an oral drug administered at doses of 960 mg and 1200 mg. It is given five days a week for seven weeks, starting one week before and continuing concurrently with radiotherapy. The purpose of ropidoxuridine is to enhance the effectiveness of radiation therapy.
The study follows a randomized, open-label design with a parallel intervention model. There is no masking involved, and the primary purpose is treatment. This straightforward design allows for direct comparison of the drug’s efficacy at different dosages.
The study began on March 24, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical update could influence Shuttle Pharmaceuticals’ stock performance positively, as successful outcomes may enhance investor confidence and market position. The study’s progress is also relevant in the context of the broader oncology market, where advancements in glioblastoma treatment are highly anticipated.
The study is currently ongoing, with further details available on the ClinicalTrials portal.